IDEXX Laboratories, Inc. (IDXX)
USD 471.9
(0.11%)
USD 471.9
(0.11%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 1.09 Billion USD | 22.07% |
| 2022 | 898.76 Million USD | -3.57% |
| 2021 | 932.02 Million USD | 34.2% |
| 2020 | 694.52 Million USD | 25.63% |
| 2019 | 552.84 Million USD | 12.52% |
| 2018 | 491.33 Million USD | 18.96% |
| 2017 | 413.02 Million USD | 17.93% |
| 2016 | 350.23 Million USD | 16.78% |
| 2015 | 299.91 Million USD | 15.24% |
| 2014 | 260.25 Million USD | -2.44% |
| 2013 | 266.76 Million USD | 1.6% |
| 2012 | 262.56 Million USD | 11.15% |
| 2011 | 236.22 Million USD | 15.86% |
| 2010 | 203.88 Million USD | 15.86% |
| 2009 | 175.96 Million USD | 2.04% |
| 2008 | 172.45 Million USD | 26.64% |
| 2007 | 136.18 Million USD | 6.45% |
| 2006 | 127.93 Million USD | 10.93% |
| 2005 | 115.33 Million USD | 6.75% |
| 2004 | 108.03 Million USD | 34.39% |
| 2003 | 80.38 Million USD | 22.14% |
| 2002 | 65.81 Million USD | 16.38% |
| 2001 | 56.55 Million USD | 6.2% |
| 2000 | 53.25 Million USD | 13.78% |
| 1999 | 46.8 Million USD | 60.82% |
| 1998 | 29.1 Million USD | 761.36% |
| 1997 | -4.4 Million USD | -109.36% |
| 1996 | 47 Million USD | 42.86% |
| 1995 | 32.9 Million USD | 44.3% |
| 1994 | 22.8 Million USD | 64.03% |
| 1993 | 13.9 Million USD | 172.55% |
| 1992 | 5.1 Million USD | 96.15% |
| 1991 | 2.6 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 298.95 Million USD | 21.87% |
| 2024 Q2 | 265.52 Million USD | -11.18% |
| 2024 Q3 | 302.17 Million USD | 14.45% |
| 2023 Q3 | 275.28 Million USD | -7.04% |
| 2023 Q2 | 296.14 Million USD | 5.62% |
| 2023 Q1 | 280.39 Million USD | 23.78% |
| 2023 FY | 1.09 Billion USD | 22.07% |
| 2023 Q4 | 245.3 Million USD | -10.89% |
| 2022 Q3 | 244.82 Million USD | 36.73% |
| 2022 Q1 | 248.34 Million USD | 24.68% |
| 2022 Q2 | 179.06 Million USD | -27.9% |
| 2022 FY | 898.76 Million USD | -3.57% |
| 2022 Q4 | 226.52 Million USD | -7.48% |
| 2021 Q4 | 199.19 Million USD | -11.85% |
| 2021 Q1 | 247.62 Million USD | 33.78% |
| 2021 Q2 | 259.25 Million USD | 4.7% |
| 2021 Q3 | 225.96 Million USD | -12.84% |
| 2021 FY | 932.02 Million USD | 34.2% |
| 2020 Q4 | 185.09 Million USD | 7.7% |
| 2020 Q1 | 144.32 Million USD | 24.82% |
| 2020 FY | 694.52 Million USD | 25.63% |
| 2020 Q2 | 193.24 Million USD | 33.9% |
| 2020 Q3 | 171.85 Million USD | -11.07% |
| 2019 Q1 | 133.13 Million USD | 15.42% |
| 2019 FY | 552.84 Million USD | 12.52% |
| 2019 Q4 | 115.63 Million USD | -17.29% |
| 2019 Q3 | 139.8 Million USD | -14.9% |
| 2019 Q2 | 164.27 Million USD | 23.39% |
| 2018 Q4 | 115.34 Million USD | -1.71% |
| 2018 FY | 491.33 Million USD | 18.96% |
| 2018 Q2 | 145.59 Million USD | 28.79% |
| 2018 Q1 | 113.04 Million USD | 15.58% |
| 2018 Q3 | 117.35 Million USD | -19.4% |
| 2017 Q1 | 92.24 Million USD | 10.04% |
| 2017 FY | 413.02 Million USD | 17.93% |
| 2017 Q4 | 97.8 Million USD | -2.59% |
| 2017 Q2 | 122.56 Million USD | 32.87% |
| 2017 Q3 | 100.41 Million USD | -18.07% |
| 2016 Q1 | 73.79 Million USD | 10.29% |
| 2016 FY | 350.23 Million USD | 16.78% |
| 2016 Q4 | 83.82 Million USD | -5.24% |
| 2016 Q3 | 88.45 Million USD | -15.08% |
| 2016 Q2 | 104.16 Million USD | 41.15% |
| 2015 Q3 | 71.89 Million USD | -18.58% |
| 2015 FY | 299.91 Million USD | 15.24% |
| 2015 Q1 | 72.8 Million USD | 109.2% |
| 2015 Q2 | 88.3 Million USD | 21.29% |
| 2015 Q4 | 66.91 Million USD | -6.93% |
| 2014 Q3 | 72.18 Million USD | -13.25% |
| 2014 Q1 | 70.04 Million USD | 14.22% |
| 2014 FY | 260.25 Million USD | -2.44% |
| 2014 Q2 | 83.21 Million USD | 18.81% |
| 2014 Q4 | 34.8 Million USD | -51.79% |
| 2013 Q1 | 61.18 Million USD | -3.53% |
| 2013 FY | 266.76 Million USD | 1.6% |
| 2013 Q4 | 61.32 Million USD | -6.35% |
| 2013 Q3 | 65.48 Million USD | -16.86% |
| 2013 Q2 | 78.76 Million USD | 28.72% |
| 2012 Q3 | 62.91 Million USD | -17.02% |
| 2012 Q2 | 75.81 Million USD | 25.51% |
| 2012 Q1 | 60.4 Million USD | 9.24% |
| 2012 FY | 262.56 Million USD | 11.15% |
| 2012 Q4 | 63.42 Million USD | 0.82% |
| 2011 Q4 | 55.29 Million USD | -1.42% |
| 2011 FY | 236.22 Million USD | 15.86% |
| 2011 Q1 | 53.53 Million USD | 5.37% |
| 2011 Q2 | 71.29 Million USD | 33.19% |
| 2011 Q3 | 56.09 Million USD | -21.32% |
| 2010 FY | 203.88 Million USD | 15.86% |
| 2010 Q4 | 50.8 Million USD | 1.99% |
| 2010 Q3 | 49.81 Million USD | -9.16% |
| 2010 Q2 | 54.83 Million USD | 13.23% |
| 2010 Q1 | 48.42 Million USD | 9.7% |
| 2009 FY | 175.96 Million USD | 2.04% |
| 2009 Q3 | 44.2 Million USD | -10.11% |
| 2009 Q2 | 49.17 Million USD | 27.93% |
| 2009 Q1 | 38.44 Million USD | 7.23% |
| 2009 Q4 | 44.14 Million USD | -0.13% |
| 2008 FY | 172.45 Million USD | 26.64% |
| 2008 Q3 | 38.99 Million USD | -33.78% |
| 2008 Q2 | 58.89 Million USD | 52.1% |
| 2008 Q4 | 35.84 Million USD | -8.07% |
| 2008 Q1 | 38.71 Million USD | 5.38% |
| 2007 Q3 | 36.09 Million USD | 11.18% |
| 2007 Q2 | 32.46 Million USD | 5.15% |
| 2007 Q1 | 30.87 Million USD | 4.77% |
| 2007 FY | 136.18 Million USD | 6.45% |
| 2007 Q4 | 36.74 Million USD | 1.79% |
| 2006 FY | 127.93 Million USD | 10.93% |
| 2006 Q4 | 29.47 Million USD | -14.49% |
| 2006 Q3 | 34.46 Million USD | -6.92% |
| 2006 Q2 | 37.02 Million USD | 37.26% |
| 2006 Q1 | 26.97 Million USD | -10.63% |
| 2005 Q1 | 26.13 Million USD | 12.3% |
| 2005 FY | 115.33 Million USD | 6.75% |
| 2005 Q4 | 30.18 Million USD | 0.2% |
| 2005 Q3 | 30.12 Million USD | 4.28% |
| 2005 Q2 | 28.88 Million USD | 10.51% |
| 2004 Q2 | 31.05 Million USD | 22.74% |
| 2004 Q3 | 28.4 Million USD | -8.54% |
| 2004 Q4 | 23.27 Million USD | -18.06% |
| 2004 FY | 108.03 Million USD | 34.39% |
| 2004 Q1 | 25.3 Million USD | 65.15% |
| 2003 Q2 | 24.33 Million USD | 39.47% |
| 2003 Q1 | 17.44 Million USD | -5.69% |
| 2003 Q3 | 23.28 Million USD | -4.31% |
| 2003 Q4 | 15.32 Million USD | -34.21% |
| 2003 FY | 80.38 Million USD | 22.14% |
| 2002 Q4 | 18.5 Million USD | 1.09% |
| 2002 Q3 | 18.3 Million USD | -2.13% |
| 2002 Q2 | 18.69 Million USD | 71.77% |
| 2002 Q1 | 10.88 Million USD | -26.79% |
| 2002 FY | 65.81 Million USD | 16.38% |
| 2001 FY | 56.55 Million USD | 6.2% |
| 2001 Q2 | 15.04 Million USD | 34.5% |
| 2001 Q3 | 15.44 Million USD | 2.65% |
| 2001 Q4 | 14.86 Million USD | -3.74% |
| 2001 Q1 | 11.18 Million USD | -22.03% |
| 2000 Q2 | 13.87 Million USD | 20.6% |
| 2000 FY | 53.25 Million USD | 13.78% |
| 2000 Q4 | 14.35 Million USD | 6.19% |
| 2000 Q3 | 13.51 Million USD | -2.63% |
| 2000 Q1 | 11.5 Million USD | -10.09% |
| 1999 Q2 | 11.6 Million USD | 12.62% |
| 1999 Q3 | 12 Million USD | 3.45% |
| 1999 Q4 | 12.8 Million USD | 6.67% |
| 1999 FY | 46.8 Million USD | 60.82% |
| 1999 Q1 | 10.3 Million USD | 3.0% |
| 1998 Q2 | 6.7 Million USD | 45.65% |
| 1998 Q3 | 7.9 Million USD | 17.91% |
| 1998 Q1 | 4.6 Million USD | 611.11% |
| 1998 FY | 29.1 Million USD | 761.36% |
| 1998 Q4 | 10 Million USD | 26.58% |
| 1997 FY | -4.4 Million USD | -109.36% |
| 1997 Q1 | -400 Thousand USD | -102.94% |
| 1997 Q2 | -5.2 Million USD | -1200.0% |
| 1997 Q3 | 2 Million USD | 138.46% |
| 1997 Q4 | -900 Thousand USD | -145.0% |
| 1996 FY | 47 Million USD | 42.86% |
| 1996 Q2 | 11.1 Million USD | 15.63% |
| 1996 Q1 | 9.6 Million USD | -2.04% |
| 1996 Q4 | 13.6 Million USD | 7.09% |
| 1996 Q3 | 12.7 Million USD | 14.41% |
| 1995 Q3 | 8.9 Million USD | 11.25% |
| 1995 Q4 | 9.8 Million USD | 10.11% |
| 1995 FY | 32.9 Million USD | 44.3% |
| 1995 Q1 | 6.3 Million USD | -10.0% |
| 1995 Q2 | 8 Million USD | 26.98% |
| 1994 Q2 | 5.5 Million USD | 27.91% |
| 1994 Q3 | 5.8 Million USD | 5.45% |
| 1994 Q4 | 7 Million USD | 20.69% |
| 1994 FY | 22.8 Million USD | 64.03% |
| 1994 Q1 | 4.3 Million USD | -25.86% |
| 1993 FY | 13.9 Million USD | 172.55% |
| 1993 Q2 | 2.8 Million USD | 55.56% |
| 1993 Q4 | 5.8 Million USD | 61.11% |
| 1993 Q1 | 1.8 Million USD | 0.0% |
| 1993 Q3 | 3.6 Million USD | 28.57% |
| 1992 Q1 | 500 Thousand USD | -54.55% |
| 1992 Q4 | 1.8 Million USD | 12.5% |
| 1992 Q3 | 1.6 Million USD | 23.08% |
| 1992 FY | 5.1 Million USD | 96.15% |
| 1992 Q2 | 1.3 Million USD | 160.0% |
| 1991 Q1 | 6.3 Million USD | 0.0% |
| 1991 FY | 2.6 Million USD | 0.0% |
| 1991 Q3 | 700 Thousand USD | 40.0% |
| 1991 Q2 | 500 Thousand USD | -92.06% |
| 1991 Q4 | 1.1 Million USD | 57.14% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -97.35 Million USD | 1226.912% |
| Biodesix, Inc. | -41.34 Million USD | 2753.785% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 13860.148% |
| Castle Biosciences, Inc. | -67.97 Million USD | 1713.969% |
| DarioHealth Corp. | -56.18 Million USD | 2052.567% |
| Exact Sciences Corporation | -215.01 Million USD | 610.264% |
| Illumina, Inc. | -1.06 Billion USD | 202.631% |
| Intelligent Bio Solutions Inc. | -10.28 Million USD | 10769.157% |
| iSpecimen Inc. | -11.16 Million USD | 9922.667% |
| Standard BioTools Inc. | -76.6 Million USD | 1532.282% |
| 23andMe Holding Co. | -321.35 Million USD | 441.406% |
| Medpace Holdings, Inc. | 336.82 Million USD | -225.726% |
| NeoGenomics, Inc. | -107.73 Million USD | 1118.349% |
| Inotiv, Inc. | -81.46 Million USD | 1446.83% |
| Psychemedics Corporation | -2.92 Million USD | 37660.014% |
| Prenetics Global Limited | -52.51 Million USD | 2189.228% |
| Precipio, Inc. | -7.62 Million USD | 14498.005% |
| RadNet, Inc. | 98.69 Million USD | -1011.612% |
| Sotera Health Company | 276.69 Million USD | -296.516% |
| Star Equity Holdings, Inc. | -4.34 Million USD | 25344.547% |
| Exagen Inc. | -22.83 Million USD | 4904.169% |
| Natera, Inc. | -446.24 Million USD | 345.858% |
| Aspira Women's Health Inc. | -18.85 Million USD | 5919.69% |
| Neogen Corporation | 58.66 Million USD | -1770.221% |
| Myriad Genetics, Inc. | -123.7 Million USD | 986.926% |
| ICON Public Limited Company | 956.15 Million USD | -14.744% |
| Bionano Genomics, Inc. | -215.24 Million USD | 609.711% |
| CareDx, Inc | -101.9 Million USD | 1176.671% |
| Check-Cap Ltd. | -19.28 Million USD | 5788.433% |
| Twist Bioscience Corporation | -220.83 Million USD | 596.818% |
| Guardant Health, Inc. | -564.72 Million USD | 294.277% |
| BioNexus Gene Lab Corp. | -2.59 Million USD | 42401.553% |
| Fulgent Genetics, Inc. | -72.69 Million USD | 1609.221% |
| Sera Prognostics, Inc. | -39.82 Million USD | 2855.149% |
| OPKO Health, Inc. | -157.02 Million USD | 798.714% |
| Personalis, Inc. | -109.93 Million USD | 1097.97% |
| Applied DNA Sciences, Inc. | -10.95 Million USD | 10116.424% |
| Star Equity Holdings, Inc. | -4.34 Million USD | 25344.547% |
| MDxHealth SA | -27.32 Million USD | 4114.813% |
| Prenetics Global Limited | -52.51 Million USD | 2189.228% |
| ENDRA Life Sciences Inc. | -10.52 Million USD | 10528.245% |
| Mainz Biomed B.V. | -26.64 Million USD | 4217.625% |
| Trinity Biotech plc | -27.04 Million USD | 4156.676% |
| Neuronetics, Inc. | -30.55 Million USD | 3690.784% |
| bioAffinity Technologies, Inc. | -7.97 Million USD | 13860.148% |